

Supplementary Table 3. Quality assessment of the included studies

Study	Selection				Comparability ^a	Outcome			Total
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow-up of cohorts	
Jongs et al. (2022) [19]	*	*	*	*	*	*	*	*	8
Adamson et al. (2022) [27]	*	*	*	*	*	*	*	- ^b	7
Cherney et al. (2022) [29]	*	*	*	*	-	*	*	- ^b	6
Oshima et al. (2021) [9]	*	*	*	*	**	*	*	*	9
Kraus et al. (2021) [11]	*	*	*	*	-	*	*	- ^c	6
Zannad et al. (2022) [20]	*	*	*	*	*	*	*	- ^c	7
Chan et al. (2021) [28]	*	*	*	*	**	*	*	- ^c	8

If they adjusted for age, sex, baseline estimated glomerular filtration rate, history of cardiovascular diseases, and status or duration of diabetes mellitus. An additional * was allocated if they also adjusted for covariates that included body mass index and lipid profiles.

^aStudies were rated, ^bFollow-up rate note stated, ^cFollow-up rate <80% at 1 year.